Showing 1671-1680 of 5643 results for "".
- Medicare Plans to Phase in Changes for Office-Visit Paymentshttps://modernod.com/news/medicare-plans-to-phase-in-changes-for-office-visit-payments/2479706/The Centers for Medicare & Medicaid Services (CMS) said it will phase in changes to payments to physicians for office visits, proceeding over the objection of many medical groups with its overhaul of reimbursement for evaluation and management (E&M) services, according to a Medscape
- Aura Biosciences Names Mark De Rosch, PhD, Chief Operating Officerhttps://modernod.com/news/aura-biosciences-names-mark-de-rosch-phd-chief-operating-officer/2479008/Aura Biosciences announced the appointment of Mark De Rosch, PhD, as Chief Operating Officer. In his role, he will be responsible for leading Aura’s global operations and regulatory strategy. Dr. De Rosch brings to Aura more than 30 years of experience in leading global regulatory and deve
- FDA Grants Notal Vision Home OCT System De Novo Marketing Authorizationhttps://modernod.com/news/fda-grants-notal-vision-home-oct-scanly-de-novo-marketing-authorization/2482282/Notal Vision announced that the FDA has granted De Novo authorization for its patient self-operated Scanly Home OCT device. Designated by the FDA as a breakthrough device for patients suffering from wet age-related macular degeneration (AMD), Scanly Home OCT aims to improve persona
- Outpatient Visits Rebound for Most Specialties to Pre-COVID Levelshttps://modernod.com/news/outpatient-visits-rebound-for-most-specialties-to-pre-covid-levels/2478438/After taking a nosedive during the initial wave of the COVID-19 pandemic, then rising and plateauing, weekly outpatient visits in the United States have rebounded and now slightly exceed levels seen in late February, according to new data, Medscape
- Glaucoma Research Foundation Encourages Patients to Visit Their Eye Doctor for the Care They Need During COVID-19 Pandemichttps://modernod.com/news/glaucoma-research-foundation-encourages-patients-to-visit-their-eye-doctor-for-the-care-they-need-during-covid-19-pandemic/2478670/Glaucoma Research Foundation (GRF) announced the release of a 6-minute video designed to encourage glaucoma patients to visit their eye care provider for the care they need during the COVID-19 pandemic. The free video
- Santen Announces FDA Acceptance of Premarket Approval Application for DE-128 (MicroShunt) for Reviewhttps://modernod.com/news/santen-announces-fda-acceptance-of-premarket-approval-application-for-de-128-microshunt-for-review/2477976/Santen Pharmaceutical announced that the FDA has accepted the premarket approval (PMA) application for DE-128 (MicroShunt) for review. DE-128 is an investigational surgical glaucoma implant designed to reduce IOP in patients with primary open-angle glaucoma whose IOP is not controlled when using
- Santen Announces Topline Data for DE-128 (MicroShunt) Demonstrating Reductions in IOP and Medication Use in Patients With Glaucomahttps://modernod.com/news/santen-announces-topline-data-for-de-128-microshunt-demonstrating-reductions-in-iop-and-medication-use-in-patients-with-glaucoma/2476840/Santen Pharmaceutical announced the results of INN-005, a prospective, randomized, controlled, single-masked, multicenter study to assess the safety and effectiveness of DE-128 (MicroShunt) standalone, without concomitant cataract extraction. The study compared DE-128 implanted intraoperatively w
- Vyluma Completes Last Patient Visit for Phase 3 CHAMP Study Evaluating NVK002 for the Treatment of Myopia Progression in Childrenhttps://modernod.com/news/vyluma-completes-last-patient-visit-for-primary-analysis-of-pivotol-phase-iii-champ-study-evaluating-nvk002-for-the-treatment-of-myopia-progression-in-children/2481059/Vyluma announced that the last patient visit has been completed for the primary analysis of the pivotal phase 3 CHAMP (Childhood Atropine for Myopia Progression) clinical study. The CHAMP study has been designed, in collaboration with the FDA, to evaluate whether NVK002 eye drops are safe and eff
- Outlook Therapeutics Reports Final Visit for Last Patient in Open-Label Safety Study for ONS-5010/Lytenava (Bevacizumab-vikg)https://modernod.com/news/outlook-therapeutics-reports-final-visit-for-last-patient-in-open-label-safety-study-for-ons-5010-lytenava-bevacizumab-vikg/2478861/Outlook Therapeutics announced that the last patient completed their final visit for the ongoing open-label safety study evaluating ONS-5010/Lytenava (bevacizumab-vikg) to treat retinal diseases (NORSE THREE). Two of the three planned clinical trials for the ONS-5010/Lytenava wet age
- Vertex Aims for “Virtual Clinic Visits” to Keep Ongoing Studies on Track Amid COVID-19 Pandemichttps://modernod.com/news/vertex-aims-for-virtual-clinic-visits-to-keep-ongoing-studies-on-track-amid-covid-19-pandemic/2477483/Vertex Pharmaceuticals said that due to the COVID-19 pandemic, the company is working with clinical trial sites to enable “virtual clinic visits” and home delivery of study drugs to ensure that ongoing trials continue as planned with the correct monitoring and procedures in place. How